8-K: INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

INmune Bio Inc. reported its Q1 2025 financial results, showing a net loss of $9.7 million and provided updates on its clinical programs, including upcoming data releases and regulatory submissions.

Summary

• INmune Bio Inc. announced its financial results for the quarter ended March 31, 2025.
• The company reported a net loss attributable to common stockholders of approximately $9.7 million, compared to $11.0 million for the same quarter in 2024.
• Research and development expenses totaled approximately $7.6 million, down from $8.7 million in the prior year's quarter.
• General and administrative expenses remained relatively stable at approximately $2.3 million.
• As of March 31, 2025, the company had approximately $19.3 million in cash and cash equivalents.
• Subsequent to the quarter's end, INmune Bio raised approximately $2.1 million from the sale of common stock.
• As of May 8, 2025, there were approximately 23.2 million common shares outstanding.
• Top-line results from the MINDFuL phase 2 trial in Alzheimers are expected in the second half of June.
• The company plans to submit a Biologics License Application (BLA) with the FDA for CORDStrom in early 2026 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
• Enrollment in the Phase II portion of the INKmune trial in metastatic castration-resistant prostate cancer is expected to be completed before year end.
• The company expects to provide periodic updates on the immunologic and therapeutic response to INKmune as data becomes available.
• Initiation of Phase 2 trial of XPro in patients with treatment-resistant depression is planned once NIH funding is made available.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, the reduced net loss compared to the previous year and progress in clinical trials are encouraging. The cash position is a concern, but the recent capital raise provides some buffer.

Positives

• The net loss decreased from $11.0 million in Q1 2024 to $9.7 million in Q1 2025.
• The company has $19.3 million in cash and cash equivalents as of March 31, 2025.
• The company raised $2.1 million from the sale of common stock after the quarter ended.
• The company received a favorable written opinion from The United States Patent and Trademark Office (USPTO) on all claims in INmune Bio's international patent application PCT/US25/17028.
• The company announced a partnership with Cell and Gene Therapy Catapult to scale up CORDStrom manufacturing for commercial readiness.
• The primary trial safety endpoint for INKmune was met.

Negatives

• The company reported a net loss of $9.7 million for the quarter ended March 31, 2025.
• Research and development expenses remain high at $7.6 million for the quarter.
• The company's cash and cash equivalents decreased from $20.9 million at the end of 2024 to $19.3 million as of March 31, 2025.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization is a risk.
• CORDstrom, XPro1595 (XPro), and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved.

Future Outlook

The company anticipates top-line data from the Phase 2 Alzheimers trial in the second half of June, plans to file a BLA for CORDStrom in RDEB in early 2026, and expects to complete enrollment in the Phase II portion of the INKmune trial before year end. They also expect to provide periodic updates on the immunologic and therapeutic response to INKmune as data becomes available and initiate a Phase 2 trial of XPro in patients with treatment-resistant depression once NIH funding is made available.

Industry Context

INmune Bio is operating in the competitive biotechnology industry, focusing on inflammation and immunology. The company's progress with its DN-TNF, CORDStrom, and INKmune platforms places it among other clinical-stage companies developing novel therapies for Alzheimer's disease, RDEB, and cancer. The partnership with Cell and Gene Therapy Catapult highlights the importance of scalable manufacturing in the cell and gene therapy space.

Comparison to Industry Standards

• The company's cash position of $19.3 million is relatively low for a clinical-stage biotech company with multiple ongoing trials; comparable companies often maintain higher cash reserves to fund operations through key milestones.
• The planned BLA submission for CORDStrom in early 2026 is a significant milestone, but the timeline is longer than some competitors in the rare disease space who have accelerated approval pathways.
• The partnership with Cell and Gene Therapy Catapult is a positive step towards commercial readiness, similar to other biotech companies collaborating with specialized manufacturing organizations to ensure scalability and cost-effectiveness.

Stakeholder Impact

• Shareholders: The financial results and clinical trial updates will likely influence investor sentiment and stock price.
• Employees: Progress in clinical trials and financial stability can impact employee morale and job security.
• Patients: Positive clinical trial results could lead to new treatment options for Alzheimer's disease, RDEB, and prostate cancer.
• Partners: Collaborations, such as the one with Cell and Gene Therapy Catapult, are crucial for scaling up manufacturing and commercial readiness.

Next Steps

• Release top-line data from the Phase 2 Alzheimers trial in the second half of June.
• File a BLA for CORDStrom in RDEB in early 2026.
• Complete enrollment in the Phase II portion of INKmune in metastatic castration-resistant prostate cancer trial before year end.
• Provide periodic updates on the immunologic and therapeutic response to INKmune as data becomes available.
• Initiate Phase 2 trial of XPro in patients with treatment-resistant depression once NIH funding is made available.

Key Dates

Keywords

INmune Bio, Financial Results, Clinical Trials, CORDStrom, INKmune, XPro, Alzheimers, RDEB, Prostate Cancer, Biotechnology, Immunology, Inflammation